PREDICTING OF SHORT AND MEDIUM-TERM EFFICACY OF BIOSIMILAR INFLIXIMAB THERAPY.  DO TROUGH LEVELS/ADAS OR CLINICAL/BIOCHEMICAL MARKERS PLAY A MORE IMPORTANT ROLE?

Petra Anna Golovics  ¹     Zsuzsanna Vegh  ¹     Mariann Rutka  ²     Krisztina Barbara Gecse  ³     Anita Balint     Klaudia Farkas     János Banai     László Bene     Beata Gasztonyi     Tünde Kristóf     László Lakatos     Pal Miheller     Karoly Palatka     Árpád V. Patai     Ágnes Szabone Salamon     Tamás Szamosi     Zoltan Gabor Szepes     Gábor Tamás Tóth     Aron Vincze     Edina    
¹ Semmelweis University Faculty of Medicine 1st Dept. of Medicine, 1st Department of Medicine, Budapest, Hungary
² University of Szeged, First Department of Internal Medicine, Szeged, Hungary
³ Semmelweis University Faculty of Med

Conference
UEG Week 2016

Citation
United European Gastroenterology Journal; 2016: 2 (Supplement 1)